Moving HER2-low breast cancer predictive and prognostic data from clinical trials into the real world

Moving HER2-low breast cancer predictive and prognostic data from clinical trials into the real world

Background: Previous data, mostly from clinical trials, reported that HER2-low status is associated with low pathological complete response (pCR), and favourable prognosis. Since these findings suggest the existence of an additional breast cancer subtype, we questioned if the predictive/prognostic v...

Full description

Bibliographic Details
Main Authors: Serena Di Cosimo, Eliana La Rocca, Silva Ljevar, Maria Carmen De Santis, Marta Bini, Vera Cappelletti, Marta Valenti, Paolo Baili, Filippo G. de Braud, Secondo Folli, Gianfranco Scaperrotta, Chiara Volpi, Andrea Vingiani, Claudio Vernieri, Paolo Verderio, Rosalba Miceli, Giancarlo Pruneri
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Molecular Biosciences
Subjects:
HER2-low
breast cancer
neoadjuvant chemotherapy
predictive
prognostic
Online Access:https://www.frontiersin.org/articles/10.3389/fmolb.2022.996434/full

Internet

https://www.frontiersin.org/articles/10.3389/fmolb.2022.996434/full

Similar Items